The U.S. recently witnessed its first decline in overdose deaths in decades—a 24–27% drop in the 12 months ending September 2024, according to CDC data—marking a milestone in the long-fought battle against the opioid crisis.
This reversal has been driven by aggressive public health interventions, including widespread naloxone distribution, robust surveillance programs, and improved access to treatment.
Foremost among these efforts is the Centers for Disease Control and Prevention (CDC) Overdose Data to Action (OD2A) cooperative agreement, launched in 2019.
OD2A equips nearly 90 state and local health departments with essential surveillance tools, enabling them to track nonfatal and fatal overdoses, detect new contaminants in illicit drug supplies, and deploy life-saving strategies like naloxone distribution, telehealth services, and recovery housing.
In July 2025, however, multiple CDC insiders and public health experts, speaking to NPR and KFF Health News, revealed that the Trump administration has withheld approximately $140 million in OD2A grants—roughly half the program’s total budget for the upcoming cycle.
Officials attribute this freeze to bureaucratic confusion and cost-cutting efforts under the Department of Government Efficiency (DOGE), not policy disagreement.
State and local health departments are sounding an alarm. Chicago’s Department of Public Health, which receives about $3.4 million annually, is bracing for disruptions, uncertain whether funding will arrive in August or materialize at all.
In Maryland, potential layoffs of 28 public health workers threaten the basic ability to track overdose deaths—what Dr. Andrew Kolodny of Brandeis University has described as “the bare minimum” for effective epidemic response.
Meanwhile, Los Angeles credits OD2A grants with a record 22% drop in overdose-related fatalities in 2024.
The stakes are highest in surveillance. OD2A funding enables detection of novel fentanyl adulterants like xylazine, carfentanil, and medetomidine. Without it, communities risk flying blind, unable to respond to emerging drug threats.
Chicago’s overdose spike last May was linked to medetomidine—detected thanks to OD2A-backed lab testing—prompting a targeted public health response that reduced emergency overdoses by 23%.
The freeze comes even as President Trump signed the HALT Fentanyl Act, heightening criminal penalties for fentanyl distribution. However, the legislation fails to allocate funding for public health measures—treatment, prevention programs, or surveillance—leading experts to criticize it as symbolic and mismatched.
Meanwhile, broader HHS reorganization under Secretary RFK Jr. threatens to slash CDC funding by 44%, NIH by 40%, and lay off tens of thousands of health workers.
Health experts warn the funding freeze puts recent gains at risk. “Without the data, we’re shooting in the dark,” said Kolodny.
Chrissie Juliano from the Big Cities Health Coalition echoed the concern, warning that pulling funding from OD2A “would really send us backwards”.
Funding epidemic response isn’t just a public health necessity—it’s fiscally prudent. The opioid crisis costs the U.S. an estimated trillion dollars per year, factoring in healthcare, lost productivity, and criminal justice expenses.
Reducing overdose deaths can reduce these economic burdens substantially.
Public health departments facing the freeze are entering a “fog of planning,” uncertain how much funding—withholding or delayed—they’ll receive.
Chicago’s Jenny Hua asked pointedly, “Do you pull the plug? What tea leaves are we supposed to read?”
As surveillance systems falter and workers are laid off, clarity is lacking, but the likely result is fewer resources to track and stop future overdoses.
READ MORE
Coca‑Cola to Launch Cane Sugar‑Sweetened Coke in U.S. This Fall
High Caffeine Intake Linked to Lower Constipation Risk in Adults
CPSC Recalls Over 5 Million Pools Following 9 Toddler Drownings
